Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH)
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), a clinical-stage biopharmaceutical company yesterday announced positive top line results from their Phase 3 INGITE4 clinical trial.
INGITE4 is a clinical trial evaluating eravacycline to meropenem for the treatment of patients with intra-abdominal infections.
The study showed that eravacycline showed statistical non-inferiority to meropenem for the primary efficacy endpoint. Eravacycline achieved its primary endpoint in the second of two crucial trials.
Tetraphase Pharmaceuticals, Inc. CEO’s Comments
“The successful outcome of this second of two pivotal phase 3 trials investigating twice-daily IV eravacycline for the treatment of cIAI is a critical achievement for Tetraphase as we continue preparations to submit our first NDA to the FDA for IV eravacycline, which we expect in the first quarter of 2018,” said Guy Macdonald, President and CEO of Tetraphase. “I would like to express my sincere gratitude to all of the patients and physicians that participated in the IGNITE4 and IGNITE1 studies. We believe that eravacycline has the potential to play a key role in the treatment of serious hospital infections, and we are another step closer to realizing that goal.”
TTPH Technical Analysis
TTPH opened trading yesterday at $7.32 which was up from the previous day’s trading close of $7.30. TTPH closed trading yesterday at $6.90 and spiked up after market to $8.70, equivalent to a 26% increase from the closing price. Taking a look at the daily chart we can see the last time TTPH traded above these levels we have to go back to April 4th when it traded at $8.71.
Taking a closer look at the daily chart we can see that before the spike up TTPH had been in an overall downward trend dating back to April 3rd when it traded at $9.22. TTPH has a float of 37.78 million shares and traded 2.86 times the normal daily trading volume on Tuesday.
For day trading purposes, I would like to see TTPH open trading on Wednesday above $8.10 and if it does I would be looking to take a long position at the bell. My stop loss would be $0.20 from my entry position fearing anything more than that and the stock would start to fill in the gap up.
Company Profile
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
The company has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.
It is also developing TP-271, a preclinical compound that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a second-generation Gram-negative program, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections.
In addition, the company is involved in the discovery and development of additional antibiotics for the treatment of unmet medical needs, including multidrug-resistant Gram-negative bacteria. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.